Ainos, Inc.

Initial license payment tied to near-term contractual delivery; additional payment opportunities may arise during development, before drug approval Partner assumes assigned clinical and regulatory funding and execution, reducing Ainos' independent capital and staffing requirements Ainos retains existing platform ownership and 25% of applicable net sublicensing revenue; potential economic participation extends beyond the $10 million licensing framework HOUSTON, TX / ACCESS Newswire / September 28, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today detailed the financial and strategic benefits of the VELDONA® License Agreement announced on September 24, 2026 (the "Agreement"). Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied.

Ainos, Inc. (NASDAQ: AIMD - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totaling 55,787 shares, a growth of 172.6% from the August 31st total of 20,463 shares. Currently, 0.8% of the company's shares are short sold. Based on an average

Partner-funded development marks an important milestone for VELDONA, with BioPhoenix funding and advancing clinical and regulatory development for two initial indications Development funding is additional to the framework; Ainos retains core platform ownership, product supply opportunities and contractual participation in downstream commercial revenue HOUSTON, TX / ACCESS Newswire / September 24, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has entered into a VELDONA® License Agreement with BioPhoenix Co., Ltd. ("BioPhoenix"), establishing a collaboration framework with a potential aggregate value of $10 million.

Report points to front-end semiconductor orders, a $2.1 million back-end program and continued dataset expansion as key indicators of Ainos' growing commercial scale HOUSTON, TX / ACCESS Newswire / September 16, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company") today highlighted a new research update from VASRO GmbH that points to strengthening commercial momentum for Ainos' AI Nose platform across semiconductor applications, supported by initial front-end orders, an established back-end subscription program and a proprietary real-world chemical dataset that has surpassed 1 billion records. VASRO highlighted two developments that it views as important markers in Ainos' semiconductor commercialization: the transition of its front-end semiconductor program from validation to initial commercial orders, and the expansion of its proprietary real-world chemical dataset beyond 1 billion records.

Initial commercial orders mark progress toward broader commercial adoption and support revenue-generation opportunities beginning in 2H 2026 Proprietary real-world chemical dataset surpasses 1 billion records, strengthening Ainos' Chemical Intelligence foundation HOUSTON, TX / ACCESS Newswire / September 14, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its second-generation AI Nose platform is advancing into commercial deployment in front-end semiconductor manufacturing, building on validation activities initiated earlier this year involving approximately 200 AI Nose systems. Ainos is receiving initial commercial orders from a front-end semiconductor company.

New patents cover electronic nose integration with robotics, expanding Ainos' portfolio of 124 patent assets worldwide across chips, sensing architectures, chemical molecules and real-world applications HOUSTON, TX / ACCESS Newswire / September 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has secured three new Japanese patents covering AI Nose technologies and their integration with robotic systems. The newly granted patents cover gas exchange, rapid chemical detection and electronic nose integration with robots: Electronic nose with gas exchange system and robot equipped with electronic nose Electronic nose and robot capable of rapid detection Electronic nose for rapid detection and robot equipped with electronic nose The patents expand Ainos' intellectual property portfolio as artificial intelligence increasingly moves beyond digital environments and into the physical world through robots, autonomous machines and other Physical AI systems.